Recent Updates
Recently added Catalysts

Stannous Fluoride

Phase 3

Dentine Hypersensitivity | Small molecule | Other |GSK plc|Last Updated: Jan 31, 2020

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindACTIVE_CONTROLLED
Total Trials4
Total Enrollment472

FDA Designations

No designations recorded

Clinical trial landscape

Stannous Fluoride · 6 trials · 3 indications

Phase 3 6
NCT02832375Investigating the Efficacy of an Occluding Dentifrice in Providing Relief From Dentinal HypersensitivityDentin Sensitivity
COMPLETED242 Analytics
NCT04123665A Phase 3 Clinical Study Investigating the Gingivitis Efficacy of a Test Dentifrice Containing Stannous FluorideGingivitis
COMPLETED98 Analytics
NCT01827670Investigating the Efficacy of a Dentifrice in Providing Long Term Relief From Dentinal HypersensitivityDentine Hypersensitivity
COMPLETED119 Analytics
NCT01592851Clinical Efficacy of a Toothpaste in Providing Relief From the Pain of Dentinal HypersensitivityDentine Hypersensitivity
COMPLETED113 Analytics
NCT03072719The Efficacy of a Dentifrice in Providing Relief From Immediate and Short Term Relief From Dentinal HypersensitivityDentine Hypersensitivity
COMPLETED120 Analytics
NCT01592864The Efficacy of a Dentifrice in Providing Relief From the Pain of Dentinal HypersensitivityDentine Hypersensitivity
COMPLETED120 Analytics
PHASE3COMPLETED
Investigating the Efficacy of an Occluding Dentifrice in Providing Relief From Dentinal Hypersensitivity
Dentin SensitivityUnlock trial analytics
PHASE3COMPLETED
A Phase 3 Clinical Study Investigating the Gingivitis Efficacy of a Test Dentifrice Containing Stannous Fluoride
GingivitisUnlock trial analytics
PHASE3COMPLETED
Investigating the Efficacy of a Dentifrice in Providing Long Term Relief From Dentinal Hypersensitivity
Dentine HypersensitivityUnlock trial analytics
PHASE3COMPLETED
Clinical Efficacy of a Toothpaste in Providing Relief From the Pain of Dentinal Hypersensitivity
Dentine HypersensitivityUnlock trial analytics
PHASE3COMPLETED
The Efficacy of a Dentifrice in Providing Relief From Immediate and Short Term Relief From Dentinal Hypersensitivity
Dentine HypersensitivityUnlock trial analytics
PHASE3COMPLETED
The Efficacy of a Dentifrice in Providing Relief From the Pain of Dentinal Hypersensitivity
Dentine HypersensitivityUnlock trial analytics

Study Endpoints

Primary Endpoints

Change From Baseline in Schiff Sensitivity Score on Day 3
Baseline, Day 3

Schiff sensitivity score was assessed by examiner as participant's response to an evaporative (air) stimulus after the stimulation of each individual tooth. Response of participant was scored using Schiff sensitivity scale range of 0-3; 0=Participant does not respond to air stimulation; 1=Participant responds to air stimulus but does not request discontinuation of stimulus; 2=Participant responds to air stimulus and requests discontinuation or moves from stimulus; 3= Participant responds to stimulus, considers stimulus to be painful, and requests discontinuation of the stimulus. A reduction in Schiff Sensitivity score indicates improvement in sensitivity.

Evaluation and Comparison of Gingival Health Measured by Bleeding Index (BI) at 24 Weeks
At Week 24

BI-to assess bleeding elicited on probing as a measure of gingival condition. Gingivae were air dried and examiner assessed bleeding using a probe which was gently inserted into gingival crevice to depth of approximately(app)1millimeter(mm)and run around tooth(angle of app60\[degrees(deg)\] to long axis of tooth), gently stretching epithelium while sweeping from interproximal to interproximal along sulcular epithelium. BI assessed on facial and lingual gingival surfaces of each scorable tooth(7in each arch). 3scores were recorded buccally/labially,3scores lingually/palatally. All scorable teeth in one quadrant were probed first(app30seconds\[sec\])before recording number of gingival units which bled. Values presented as means across all tooth surfaces with minimum and maximum scores in agreement with minimum and maximum index values(i.e.,0-2).BI score:0=no bleeding after30sec,1=bleeding upon probing after30sec,2=immediate bleeding observed. Lower scores indicate better results.

Mean Change From Baseline in Schiff Sensitivity Score
Baseline-Week 8

The examiner conducted the evaporative air sensitivity assessment and scored the subject's response to the sensitivity stimulus using the four-point categorical Schiff Sensitivity Scale (SSS). Score 0 = Subject does not respond to air stimulus Score 1 = Subject responds to air stimulus, but does not request discontinuation of stimulus Score 2 = Subject responds to air stimulus, and requests discontinuation or moves from stimulus Score 3 = Subject responds to air stimulus, considers stimulus to be painful, and requests discontinuation

Change From Baseline in Evaporative Air Sensitivity Pain Response on a Schiff Sensitivity Scale at Day 14
Baseline to Day 14

Response to a constant jet of air applied to hypersensitive teeth is evaluated using a Schiff Sensitivity pain response scale. According to this analog scale, pain response for each individual stimulated tooth ranged from 0 to 3; 0 - participant does not respond to air stimulation, 1 - participant responds to air stimulus but does not request discontinuation of stimulus, 2 - participant responds to air stimulus and request discontinuation of stimulus, 3 - participant responds to air stimulus, considers stimulus to be painful and request discontinuation of stimulus. Those teeth that met the tactile threshold inclusion criterion (tactile threshold ≤ 20g) were assessed at baseline and Day 14. The Investigator directed a second application of air from a standard dental syringe to the facial surface of the two sensitive teeth selected at baseline. The Schiff Sensitivity Score was calculated as the subject level mean change (on two teeth) from baseline.

Change From Baseline in Schiff Sensitivity Score on Day 14
Baseline, Day 14

Schiff sensitivity score was assessed by examiner as participant's response to an evaporative (air) stimulus after the stimulation of each individual tooth. Response of participant was scored using Schiff sensitivity scale range of 0-3; 0=Participant does not respond to air stimulation; 1=Participant responds to air stimulus but does not request discontinuation of stimulus; 2=Participant responds to air stimulus and requests discontinuation or moves from stimulus; 3= Participant responds to stimulus, considers stimulus to be painful, and requests discontinuation of the stimulus. A reduction in Schiff Sensitivity score indicates improvement in sensitivity.

Mean Change From Baseline in Evaporative Air Sensitivity Pain Response on a Schiff Sensitivity Scale at Week 8
Baseline to 8 weeks post administration of study treatment

Response to a constant jet of air applied to hypersensitive teeth is evaluated using a Schiff Sensitivity pain response scale. According to this analog scale, pain response for each individual stimulated tooth ranged from 0 to 3; 0 - participant does not respond to air stimulation, 1 - participant responds to air stimulus but does not request discontinuation of stimulus, 2 - participant responds to air stimulus and request discontinuation of stimulus, 3 - participant responds to air stimulus, considers stimulus to be painful and request discontinuation of stimulus.

Secondary Endpoints

Change From Baseline in Schiff Sensitivity Score After Single Use
Baseline, after single use (after 5 minutes)
Change From Baseline in Tactile Threshold Immediately After Single Use and on Day 3
Baseline, after single use (after 5 minutes) and on Day 3
Evaluation and Comparison of Gingival Health Measured by BI at 12 Weeks
At Week 12
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Experimental: stannous fluorideEXPERIMENTALParticipants will be instructed to dose a dry toothbrush containing 0.454% w/w of stannous fluoride (1000 parts per million \[ppm\] fluoride) with a full strip (1 inch) of toothpaste. Participants will then brush each of the two selected sensitive test teeth first followed by the whole mouth thoroughly for at least 1 minute.
Standard: sodium monofluorophosphateACTIVE_COMPARATORParticipants will be instructed to dose a dry toothbrush containing 0.76% w/w sodium monofluorophosphate (1000ppm fluoride) with a full strip (1 inch) of toothpaste. Participants will then brush each of the two selected sensitive test teeth first followed by the whole mouth thoroughly for at least 1 minute.
Experimental Test DentifriceEXPERIMENTALIn this arm, participants will apply a full ribbon of dentifrice ( 0.454% w/w stannous fluoride) to the bristles of a study toothbrush and brush their teeth in their usual manner for one timed minute twice daily (morning and evening) and record on their study diary completed brushings.
Control DentifricePLACEBO_COMPARATORIn this arm, participants will apply a full ribbon of negative control dentifrice (1000 ppm fluoride as sodium monofluorophosphate \[SMFP\] to the bristles of a study toothbrush and brush their teeth in their usual manner for one timed minute twice daily (morning and evening) and record on their study diary completed brushings.
0.454% stannous fluoride dentifriceEXPERIMENTALParticipants to brush whole mouth with 1-inch strip of the test dentifrice (0.454% SnF) for one timed minute, followed by rinsing with 5 milliliter (mL) of water.
0.76% sodium monofluorophosphate dentifriceACTIVE_COMPARATORParticipants to brush whole mouth with 1-inch strip of the control dentifrice (0.76% NaMFP) for one timed minute, followed by rinsing with 5 mL of water.
Arm 1EXPERIMENTALDentifrice containing stannous fluoride
Arm 2ACTIVE_COMPARATORMarketed dentifrice containing Sodium Monofluorophosphate
Dentifrice containing stannous fluorideEXPERIMENTALToothpaste
Dentifrice containing Sodium MonofluorophosphateACTIVE_COMPARATORToothpaste

Interventions

NameTypeDescription
stannous fluorideDRUG0.454% w/w stannous fluoride containing 1100ppm of fluoride
sodium monofluorophosphateDRUG0.76% w/w sodium monofluorophosphate containing 1000ppm fluoride
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 65 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Demonstrates understanding of the study and willingness to participate as evidenced by voluntary written informed consent and has received a signed and dated copy of the informed consent form. * Aged 18-65 years inclusive * Understands and is willing, able and likely to comply...

Countries:United StatesIreland
Unlock Eligibility Criteria

Frequently asked questions about Stannous Fluoride

What is Stannous Fluoride used for?

Stannous Fluoride is used for dentine hypersensitivity, dentin sensitivity, and gingivitis. It is being investigated in Phase 3 clinical trials as a dentifrice ingredient to provide relief from dentinal hypersensitivity and to reduce gingivitis. The compound is developed by GSK plc.

Who makes Stannous Fluoride?

Stannous Fluoride is developed by GSK plc, a pharmaceutical company listed on the stock exchange under the ticker GSK. GSK is conducting Phase 3 clinical trials to evaluate the efficacy of Stannous Fluoride in treating dentine hypersensitivity, dentin sensitivity, and gingivitis.

What phase is Stannous Fluoride in?

Stannous Fluoride is in Phase 3 clinical development. It is an investigational compound being studied for dentine hypersensitivity, dentin sensitivity, and gingivitis. All four Phase 3 trials have been completed, with a total enrollment of 472 participants across the United States and Ireland.

What clinical trials is Stannous Fluoride in?

Stannous Fluoride has been studied in four completed Phase 3 trials: NCT01827670 and NCT03072719 for dentine hypersensitivity, NCT02832375 for dentin sensitivity, and NCT04123665 for gingivitis. These trials enrolled 119, 120, 242, and 98 participants respectively, all aged 18 years and older.

Is Stannous Fluoride the same as stannous fluoride in toothpaste?

Stannous Fluoride is a chemical compound commonly used in toothpaste formulations. In clinical trials, it is being evaluated as a dentifrice ingredient for its efficacy in providing relief from dentinal hypersensitivity and reducing gingivitis. The trials are active-controlled, randomized, and double-blind.